Dual PI3K/mTOR inhibitor with reduced brain penetration for use in oncology or other therapeutic areas.
Multiple indications in metastatic breast cancer, early breast cancer and metastatic gastric cancer
Multiple indications in Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL), Rheumatoid arthritis, Granulomatosis with polyangiitis and microscopic polyangiitis and Pemphigus vulgaris